Pfizer explores sale of hospital drugs unit
FDA declines full approval for Intercept's liver disease drug
AstraZeneca lifts 2024 forecast on better than expected Q3 performance
Pfizer and Lilly’s telehealth prescribing platforms draw Senate scrutiny for ‘potential fraud’
*please scroll down for all the latest news*
